About
There is a strong unmet need in HS treatment. The pathophysiology of HS is most likely multifactorial, including genetic, immune and microbiological factors. Specific pathobionts in HS lesions have been identified by our team. Antibiotics are widely used to treat HS and clinical remission of the disease has been obtained prospectively in 14/17 Hurley stage 2 patients at the Institut Pasteur Medical Center with an adapted antibiotic strategy.
The objective is to demonstrate the superiority of a 3–week course of a ceftriaxone+metronidazole treatment followed by 3 weeks of a rifampin+moxifloxacin+metronidazole combination, then 6 weeks of rifampin+moxifloxacin (experimental treatment) over a 12-week course of a tetracycline derivative in patients with Hurley stage 2 HS at week 12 in a multicentric randomized double-blind phase 3 trial.
Collaborators:
- Centre Médical de l’Institut Pasteur, Paris
- Hôpital Saint Joseph, Paris
- Hôpital Edouard Herriot, Lyon
- Hôpital de la Timone, Marseille
- CHU de Rouen
- ICAREB-Clin, Institut Pasteur
- ICAREB-Biobank, Institut Pasteur
- PC-RC, Institut Pasteur
- Laboratoire de Microbiologie du CHU de Caen